AGP Picks
View all

Puerto Rico Technology Today
Provided by AGP

Puerto Rico Technology Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Puerto Rico Technology Today.

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

Press releases published on June 3, 2026

Cherry Bekaert Selects Fieldguide as Strategic AI Partner to Modernize Audit and Advisory Delivery
Jun. 3, 2026

Cherry Bekaert Selects Fieldguide as Strategic AI Partner to Modernize Audit and Advisory Delivery

Indeterminate GlobeNewswire
SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma
Jun. 3, 2026

SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma

Indeterminate GlobeNewswire
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Jun. 3, 2026

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Indeterminate GlobeNewswire
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Jun. 3, 2026

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Indeterminate GlobeNewswire
AlphaSense Raises $350M at $7.5B Valuation, and Surpasses $600M in Annual Recurring Revenue
Jun. 3, 2026

AlphaSense Raises $350M at $7.5B Valuation, and Surpasses $600M in Annual Recurring Revenue

Indeterminate GlobeNewswire
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
Jun. 3, 2026

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Indeterminate GlobeNewswire
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Jun. 3, 2026

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Indeterminate GlobeNewswire
AlphaSense Introduces SuperAnalyst: The Always-On AI Agent for Decision-Grade Intelligence
Jun. 3, 2026

AlphaSense Introduces SuperAnalyst: The Always-On AI Agent for Decision-Grade Intelligence

Indeterminate GlobeNewswire
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Jun. 3, 2026

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Indeterminate GlobeNewswire
Richtech Robotics Completes Strategic Acquisition of Warehouse Facility in Las Vegas to Accommodate Robotics and AI Powered Growth Objectives
Jun. 3, 2026

Richtech Robotics Completes Strategic Acquisition of Warehouse Facility in Las Vegas to Accommodate Robotics and AI Powered Growth Objectives

Indeterminate GlobeNewswire
Denovo to Participate in Upcoming Investor Conferences Highlighting its Biomarker Guided Phase 3 Antidepressant
Jun. 3, 2026

Denovo to Participate in Upcoming Investor Conferences Highlighting its Biomarker Guided Phase 3 Antidepressant

Indeterminate GlobeNewswire
Aduro Appoints Senior European Industrial Leader to Lead Delivery of FOAK Facility at Chemelot
Jun. 3, 2026

Aduro Appoints Senior European Industrial Leader to Lead Delivery of FOAK Facility at Chemelot

Indeterminate GlobeNewswire
NextGen Pathology Selects Proscia to Establish AI Foundation for Business Growth
Jun. 3, 2026

NextGen Pathology Selects Proscia to Establish AI Foundation for Business Growth

Indeterminate GlobeNewswire
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Jun. 3, 2026

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Indeterminate GlobeNewswire
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Jun. 3, 2026

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Indeterminate GlobeNewswire
Diginex Provides Update on Proposed Resulticks Acquisition
Jun. 3, 2026

Diginex Provides Update on Proposed Resulticks Acquisition

Indeterminate GlobeNewswire
RAID: Shadow Legends Launches ‘Web of Corruption’ Event
Jun. 3, 2026

RAID: Shadow Legends Launches ‘Web of Corruption’ Event

Indeterminate GlobeNewswire
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
Jun. 3, 2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Indeterminate GlobeNewswire
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
Jun. 3, 2026

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

Indeterminate GlobeNewswire
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
Jun. 3, 2026

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

Indeterminate GlobeNewswire
Show More

Share this page:

Sign up for:

Puerto Rico Technology Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.